scholarly journals Meta-Analyses of Microarray Datasets Identifies ANO1 and FADD as Prognostic Markers of Head and Neck Cancer

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0147409 ◽  
Author(s):  
Ram Bhupal Reddy ◽  
Anupama Rajan Bhat ◽  
Bonney Lee James ◽  
Sindhu Valiyaveedan Govindan ◽  
Rohit Mathew ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prognostic Markers ◽  
Meta Analyses ◽  
Microarray Datasets

scholarly journals Clinical significance of tumor-stroma ratio in head and neck cancer: a systematic review and meta-analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Alhadi Almangush ◽  
Rasheed Omobolaji Alabi ◽  
Giuseppe Troiano ◽  
Ricardo D. Coletta ◽  
Tuula Salo ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Clinical Significance ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Tumor Stroma ◽  
Free Survival ◽  
Hematoxylin And Eosin ◽  
Meta Analyses

Abstract Background The clinical significance of tumor-stroma ratio (TSR) has been examined in many tumors. Here we systematically reviewed all studies that evaluated TSR in head and neck cancer. Methods Four databases (Scopus, Medline, PubMed and Web of Science) were searched using the term tumo(u)r-stroma ratio. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) were followed. Results TSR was studied in nine studies of different subsites (including cohorts of nasopharyngeal, oral, laryngeal and pharyngeal carcinomas). In all studies, TSR was evaluated using hematoxylin and eosin staining. Classifying tumors based on TSR seems to allow for identification of high-risk cases. In oral cancer, specifically, our meta-analysis showed that TSR is significantly associated with both cancer-related mortality (HR 2.10, 95%CI 1.56–2.84) and disease-free survival (HR 1.84, 95%CI 1.38–2.46). Conclusions The assessment of TSR has a promising prognostic value and can be implemented with minimum efforts in routine head and neck pathology.

scholarly journals Obstructive Sleep Apnoea in Patients Treated for Head and Neck Cancer: A Systematic Review of the Literature

Medicina ◽  
2020 ◽  
Vol 56 (8) ◽  
pp. 399
Author(s):  
Massimo Ralli ◽  
Flaminia Campo ◽  
Diletta Angeletti ◽  
Eugenia Allegra ◽  
Antonio Minni ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Obstructive Sleep Apnoea ◽  
Neck Cancer ◽  
Sleep Apnoea ◽  
Partial Laryngectomy ◽  
Population Differences ◽  
Obstructive Sleep ◽  
Meta Analyses

Background and objectives: Obstructive sleep apnoea (OSA) is clinically defined by signs of daytime sleepiness and objective measures of disordered breathing during sleep. The literature is still controversial on the incidence and aetiology of OSA secondary to head and neck cancer treatment. The aim of this systematic review is to evaluate and discuss the prevalence of OSA in patients treated with surgery and/or chemo/radiotherapy for head and neck cancer. Materials and methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search was performed on May 2020 using the MEDLINE database, Scopus, and Google Scholar. The searches were conducted using combinations of the following terms: head and neck cancer, OSA, radiotherapy, chemotherapy, partial laryngectomy, laryngeal cancer, neoplasm, tumour, carcinoma, and oropharyngeal cancer. Results: Our results suggest that head and neck cancer patients have a higher incidence of OSA (59.78%) compared to the general population; differences may occur based on the type of treatment. Conclusions: Clinicians should recognise the higher prevalence of OSA in patients treated for head and neck cancer and should consider a comprehensive sleep history as part of the evaluation and management of these patients. Further research is needed to evaluate the exact prevalence, aetiology, and correct management of OSA after treatment for head and neck cancer.

scholarly journals Evidence-Based Guidelines for Management of Head and Neck Mucosal Malignancies during the COVID-19 Pandemic

2020 ◽  
Vol 163 (1) ◽  
pp. 16-24 ◽  
Author(s):  
Dana L. Crosby ◽  
Arun Sharma
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Current Evidence ◽  
Evidence Based ◽  
Sources Of Information ◽  
Care Plans ◽  
Increased Risk ◽  
National Organizations ◽  
Meta Analyses

Objective Due to the current coronavirus disease 2019 (COVID-19) pandemic, otolaryngologists face novel challenges when treating patients with head and neck cancer. The purpose of this review is to evaluate the current evidence surrounding the treatment of these patients during this pandemic and to provide evidence-based recommendations with attention to increased risk in this setting. Data Sources A review of the literature was performed with PubMed. Because recently published articles on this topic may not yet be indexed into PubMed, otolaryngology journals were hand searched for relevant articles. Guidelines from national organizations were reviewed to identify additional relevant sources of information. Review Methods Two groups of search terms were created: one with terms related to COVID-19 and another with terms related to head and neck cancer and its management. Searches were performed of all terms in each group as well as combinations of terms between groups. Searches and subsequent exclusion of articles were performed in accordance with the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses). Additional articles were identified after relevant journals and guidelines from national organizations were reviewed. Conclusions Patients with head and neck mucosal malignancy require continued treatment despite the current pandemic state. Care must be taken at all stages of treatment to minimize the risk to patients and health care workers while maintaining focus on minimizing use of limited resources. Implications for Practice Patient care plans should be guided by best available evidence to optimize outcomes while maintaining a safe environment in the setting of this pandemic.

Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update

2007 ◽  
Vol 69 (2) ◽  
pp. S112-S114 ◽  
Author(s):  
Jean-Pierre Pignon ◽  
Aurélie le Maître ◽  
Jean Bourhis
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Meta Analyses

scholarly journals Effectiveness of Adjunctive Analgesics in Head and Neck Cancer Patients Receiving Curative (Chemo-) Radiotherapy: A Systematic Review

Pain Medicine ◽  
2020 ◽  
Author(s):  
Tessa Lefebvre ◽  
Laura Tack ◽  
Michelle Lycke ◽  
Fréderic Duprez ◽  
Laurence Goethals ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cochrane Collaboration ◽  
Cochrane Library ◽  
Head Neck Cancer ◽  
High Quality ◽  
Pain Outcome ◽  
Meta Analyses

Abstract Objective Our aim was to give an overview of the effectiveness of adjunctive analgesics in head and neck cancer (HNC) patients receiving (chemo-) radiotherapy. Design Systematic review. Interventions This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched for studies concerning “head neck cancer,” “adjunctive analgesics,” “pain,” and “radiotherapy.” Outcome Measures Pain outcome, adverse events, and toxicity and other reported outcomes, for example, mucositis, quality of life, depression, etc. Results Nine studies were included in our synthesis. Most studies were of low quality and had a high risk of bias on several domains of the Cochrane Collaboration tool. Only two studies comprised high-quality randomized controlled trials in which pregabalin and a doxepin rinse showed their effectiveness for the treatment of neuropathic pain and pain from oral mucositis, respectively, in HNC patients receiving (chemo-) radiotherapy. Conclusions More high-quality trials are necessary to provide clear evidence on the effectiveness of adjunctive analgesics in the treatment of HNC (chemo-) radiation-induced pain.

scholarly journals Validation of Selected Head and Neck Cancer Prognostic Markers from the Pathology Atlas in an Oral Tongue Cancer Cohort

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2387
Author(s):  
Anna Maria Wirsing ◽  
Inger-Heidi Bjerkli ◽  
Sonja Eriksson Steigen ◽  
Oddveig Rikardsen ◽  
Synnøve Norvoll Magnussen ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prognostic Value ◽  
Prognostic Markers ◽  
Multivariate Analyses ◽  
Tongue Cancer ◽  
Cancer Tissue ◽  
Oral Tongue ◽  
Protein Coding

The Pathology Atlas is an open-access database that reports the prognostic value of protein-coding transcripts in 17 cancers, including head and neck cancer. However, cancers of the various head and neck anatomical sites are specific biological entities. Thus, the aim of the present study was to validate promising prognostic markers for head and neck cancer reported in the Pathology Atlas in oral tongue squamous cell carcinoma (OTSCC). We selected three promising markers from the Pathology Atlas (CALML5, CD59, LIMA1), and analyzed their prognostic value in a Norwegian OTSCC cohort comprising 121 patients. We correlated target protein and mRNA expression in formalin-fixed, paraffin-embedded cancer tissue to five-year disease-specific survival (DSS) in univariate and multivariate analyses. Protein expression of CALML5 and LIMA1 were significantly associated with five-year DSS in the OTSCC cohort in univariate analyses (p = 0.016 and p = 0.043, respectively). In multivariate analyses, lymph node metastases, tumor differentiation, and CALML5 were independent prognosticators. The prognostic role of the other selected markers for head and neck cancer patients identified through unbiased approaches could not be validated in our OTSCC cohort. This underlines the need for subsite-specific analyses for head and neck cancer.

scholarly journals Serum Prognostic Markers in Head and Neck Cancer

2010 ◽  
Vol 16 (3) ◽  
pp. 1008-1015 ◽  
Author(s):  
F. Meyer ◽  
E. Samson ◽  
P. Douville ◽  
T. Duchesne ◽  
G. Liu ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prognostic Markers
Sign in / Sign up

Export Citation Format

Share Document